Drugs / Vitamin K antagonists (VKA)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02832544 Comparator | Aug 2016 → Aug 2022 | rheumatic heart disease | Population Health Research Institute | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vitamin K antagonists (VKA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02832544 ↗ |
| Route | Oral | “oral anticoagulation with VKAs is recommended for stroke prevention” PMID 32474206 ↗ Mar 2020 |